Daniel C. Link

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65

  Experimental Hematology · 2026-04-17

• Synthetic lethality of decitabine plus ATR inhibition for <i>TP53</i> -mutated AML

  Blood Advances · 2026-01-29

• Persistent binding of DNMT1 to chromatin causes replication dysfunction in TP53-mutated myeloid neoplasms

  Blood · 2025-11-03

• In Vivo modeling of leukemic evolution in ELANE-associated severe congenital neutropenia

  Blood · 2025-11-03

• Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence

  Blood · 2025-11-03

• Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers

  Journal of Molecular Diagnostics · 2025-09-27 · 1 citations

• A clinical guide to <i>TP53</i> mutations in myeloid neoplasms

  Blood · 2025-07-29 · 12 citations

• Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy

  Nature Genetics · 2025-07-15 · 16 citations

• How chemotherapy shapes hematopoietic stem cells

  Nature Genetics · 2025-07-01

• Investigation of clonal hematopoiesis frequency following PARP inhibitor treatment and its association with prior platinum therapy exposure.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Abstract 2555: Multimodal atlas of cellular senescence in human bone marrow reveals insights into aging and multiple myeloma

  Cancer Research · 2025-04-21

• ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders

  Journal of Clinical Investigation · 2025-04-03 · 10 citations

• Are <i>TP53</i> mutations all alike?

  Hematology · 2024-12-06 · 9 citations

• Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

  Blood · 2024-11-05 · 1 citations

• <i>JAK2-V617F</i> Expression Results in a Cell-Intrinsic Expansion of Megakaryocyte Progenitors with Evidence of Myc Pathway Activation in Both Mature and Precursor Megakaryocytes By Single Cell RNA Sequencing

  Blood · 2024-11-05

• DNA Hypomethylation Is Not Sufficient to Account for Decitabine Mediated Cytotoxicity in <i>TP53</i>-Mutated Myeloid Malignancies

  Blood · 2024-11-05

• Germline Homologous Recombination Deficiency (HRD) Influences the Fitness Impact of Oncologic Therapy on DNA Damage Response Gene Clonal Hematopoiesis (CH)

  Clinical Lymphoma Myeloma & Leukemia · 2024-08-26

• MPN-755 Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

  Clinical Lymphoma Myeloma & Leukemia · 2024-08-26

• AML-743 Germline Homologous Recombination Deficiency (HRD) Influences the Fitness Impact of Oncologic Therapy on DNA Damage Response Gene Clonal Hematopoiesis (CH)

  Clinical Lymphoma Myeloma & Leukemia · 2024-08-26

• Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

  Clinical Lymphoma Myeloma & Leukemia · 2024-08-26